Risk of death associated with the use of conventional vs. atypical antipsychotic medications: evaluating the use of the Emilia-Romagna Region database for pharmacoepidemiological studies

2013 ◽  
Vol 39 (1) ◽  
pp. 38-44 ◽  
Author(s):  
S. Sikirica ◽  
M. Marino ◽  
J. J. Gagne ◽  
R. De Palma ◽  
V. Maio
2005 ◽  
Vol 353 (22) ◽  
pp. 2335-2341 ◽  
Author(s):  
Philip S. Wang ◽  
Sebastian Schneeweiss ◽  
Jerry Avorn ◽  
Michael A. Fischer ◽  
Helen Mogun ◽  
...  

Author(s):  
Adam P. Mecca ◽  
Rajesh R. Tampi

This chapter provides a summary of a landmark meta-analysis that investigated the risks of atypical antipsychotic use to treat psychosis, aggression, or agitation in patients with dementia. The chapter briefly reviews the study design, as well as implications and limitations. A relevant clinical case concludes the chapter. In summary, atypical antipsychotic use for 6 to 26 weeks was associated with increased risk of death (Odds Ratio of 1.54 for antipsychotic vs placebo). There were no differences in risk between individual medications, disease severity, indication for antipsychotic, or treatment setting. In patients with psychosis, agitation, or aggression due to dementia, the efficacy of atypical antipsychotics is questionable and their use comes with considerable risks of side effects and adverse events.


2001 ◽  
Vol 46 (3) ◽  
pp. 285-285 ◽  
Author(s):  
Peter F Buckley ◽  
Del D Miller ◽  
Beth Singer ◽  
Karl Donenwirth

Critical Care ◽  
2018 ◽  
Vol 22 (1) ◽  
Author(s):  
Kunal Karamchandani ◽  
Robert S. Schoaps ◽  
Jillian Printz ◽  
Jeffrey M. Kowaleski ◽  
Zyad J. Carr

2020 ◽  
Vol 22 (4) ◽  
Author(s):  
Liliana P. Ferreira ◽  
Tiago F. Ferreira ◽  
Filipe F. Godinho ◽  
Maria Carlota Tomé ◽  
Carlos J. Vieira ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document